Vertex Pharmaceuticals Incorporated (VRTX) Slid Due to Setbacks In Clinical Trials
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Wells Fargo Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $460
Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Cuts Target Price to $456
Express News | Zai Lab Ltd - to Handle Commercialization Activities for Povetacicept
Express News | Zai Lab Ltd - Vertex to Receive Upfront Payment, Milestone Payments, and Royalties
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}